# Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC

> **NCT00561054** · PHASE2 · UNKNOWN · sponsor: **Grupo Portugues de Estudo do Cancro do Pulmao** · enrollment: 47 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** CETUXIMAB

## Key facts

- **NCT ID:** NCT00561054
- **Lead sponsor:** Grupo Portugues de Estudo do Cancro do Pulmao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2007-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561054, "Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00561054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*